Cardiol Therapeutics Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: data-quality checks not passed.
Price vs value
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Cardiol Therapeutics Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds23 adding, 16 cuttingOf 7 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 48% in the quarter to 2026-06-30, the 2nd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Net cash. Cash exceeds long-term debt by $0.0bn.
Things to watch
- Loss-making. Operating margin is -49091.9%: costs exceed revenue.
- Burning cash. Free cash flow was -29904.2% of revenue over the last 12 months.
- Heavy stock-based pay. Stock pay equals 10789.5% of revenue: a real cost that cash-flow figures leave out.
- Share dilution. Diluted shares rose 21.5% in a year.
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$0.05 against an average estimate of -$0.10: beat by 48.3%
- Next report
- November 12, 2026
Price chart
- 1 day+0.5%
- 1 week-8.3%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-0.28
Growth
- Share count change
- +21.5%
Cash
- Free cash flow (TTM)
- -$17.1M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for CRDL from the sources we follow. See filings →
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, after the close.
Analysts' consensus
No analyst estimates are published for Cardiol Therapeutics Inc.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.10 | −$0.05 | +48.3% |
| Mar 2026 | −$0.09 | −$0.10 | −11.1% |
| Dec 2025 | −$0.11 | −$0.07 | +36.4% |
| Sept 2025 | −$0.10 | −$0.12 | −14.3% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 2.4% of tradable shares
- Days to cover
- 1.8 at average volume
- Short interest, 1 month
- −14% to October 15, 2026
- Held by institutions
- 27% of shares
- Held by insiders
- 2.3% of shares
- Employees
- 18 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial statements
| Fiscal year | 2021 Dec 2021 |
|---|---|
| Income | |
| Revenue | 0 |
| EBITDA | −31 |
| Operating income | −31 |
| Net income | −25 |
| Diluted EPS | −$0.58 |
| Margins | |
| EBITDA margin | <−999% |
| Operating margin | <−999% |
| Net margin | <−999% |
| Free-cash-flow margin | <−999% |
| Cash flow | |
| Cash from operations | −19 |
| Capital spending | 0 |
| Free cash flow | −19 |
| Stock-based pay | 7 |
| Free cash flow after stock pay | −26 |
| Balance sheet | |
| Cash | 66 |
| Total debt | 0 |
| Net debt (negative = net cash) | −66 |
| Diluted shares | 43m |
Financial health
- Short-term assets cover short-term liabilities $17m of assets due within a year against $4m of liabilities due within a year.
- Short-term assets cover long-term liabilities $17m short-term assets against $63,576 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +21.5%
- year over year
Competitors: side by side with peers
| Last 12 months unless stated | CRDL | PRFX | AKAN | SCNX | SXTP | SXTC | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $62858 | $17000 | $258075 | $821315 | $1m | $1m | $254m |
| Revenue growth, last 12 months | — | — | −69.2% | 540.6% | 73.2% | −34.6% | 9.9% |
| Revenue growth, 3-year average | — | — | — | −58.5% | 74.9% | — | 5.5% |
| Revenue growth, latest quarter | — | — | — | 449.1% | 106.0% | — | 6.5% |
| Gross margin | — | −311.8% | −60.5% | 87.7% | 19.4% | 21.9% | 62.0% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | −774.9% | −625.9% | −5.9% |
| Operating margin, 3-year average | — | — | — | <−999% | <−999% | −267.4% | −7.4% |
| Net margin | <−999% | <−999% | −467.1% | <−999% | −729.9% | −545.2% | −7.4% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | −789.8% | −353.0% | 9.4% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | −800.6% | −353.0% | 8.1% |
| Free-cash-flow margin, 3-year average | — | — | — | <−999% | — | −126.6% | 7.4% |
| Stock pay / revenue | >999% | >999% | 21.3% | 257.1% | 37.2% | 466.2% | 3.7% |
| Change in share count | 21.5% | 368.7% | −93.4% | 2.1% | — | >999% | 2.0% |
Who owns it
Funds buying and selling- Reported value
- $31.3M
- Institutions reporting
- 52
- Shares held vs prior quarter
- ▲ 5.8%
- Positions opened / closed
- 12 / 6
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Mmcap International Inc. Spc | $16.5M | 15.6M | 52.9% | ▲ 1.6% |
| Tejara Capital Ltd | $5.4M | 5.1M | 17.3% | ▼ 0.3% |
| Ikarian Capital, LLC | $3.5M | 3.3M | 11.3% | ▲ 22.0% |
| Boothbay Fund Management, LLC | $1M | 976K | 3.3% | ▲ 22.8% |
| Citadel Advisors LLC | $844,320 | 797K | 2.7% | ▼ 2.9% |
| Renaissance Technologies LLC | $819,207 | 773K | 2.6% | ▲ 236.3% |
| Two Sigma Investments, LP | $791,753 | 747K | 2.5% | ▲ 39.8% |
| Integrity Alliance, Llc. | $411,802 | 388K | 1.3% | ▼ 16.5% |
| Morgan Stanley | $376,332 | 355K | 1.2% | ▲ 41.8% |
| Goldman Sachs Group Inc | $353,934 | 334K | 1.1% | ▲ 0.5% |
| Pvg Asset Management Corp | $113,595 | 107K | 0.4% | 0.0% |
| 1832 Asset Management L.P. | $106,000 | 100K | 0.3% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cardiol Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Cardiol Therapeutics Inc. in brief
- What does Cardiol Therapeutics Inc. do?
- Cardiol Therapeutics Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
- What is Cardiol Therapeutics Inc.'s stock ticker?
- Cardiol Therapeutics Inc. trades under the ticker CRDL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Cardiol Therapeutics Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Mmcap International Inc. Spc, Tejara Capital Ltd and Ikarian Capital, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Who are Cardiol Therapeutics Inc.'s competitors?
- In our Pharmaceuticals peer group, the companies closest to Cardiol Therapeutics Inc. are PRF Technologies Ltd., Akanda Corp., Scienture Holdings, Inc., 60 Degrees Pharmaceuticals, Inc. and China SXT Pharmaceuticals, Inc. The side-by-side comparison below sets their revenue, margins and growth against Cardiol Therapeutics Inc.'s.
- When is Cardiol Therapeutics Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cardiol Therapeutics Inc. announces its own schedule.
Follow research on Cardiol Therapeutics Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.